SCHEMBL6192593

SCHEMBL6192593

O=C1CCc2cc(-c3cccc(Cl)c3)ccc21

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 4/20 0.64
PARP11 Q9NR21 4/20 0.64
CYP1A2 P05177 1/20 0.59
CYP11B1 P15538 1/20 0.59
CYP11B2 P19099 1/20 0.59
HSD17B1 P14061 4/20 0.58
TDP2 O95551 2/20 0.56
PGR P06401 5/20 0.52
CASP1 P29466 1/20 0.47
CASP7 P55210 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
GRM5 P41594 1/20 0.44
ALOX5 P09917 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4563338 0.90 PARP10 (0.61) PARP10PARP11CYP1A2CYP11B1CYP11B2
SCHEMBL3987535 0.86 HSD17B1 (0.62) PARP10PARP11CYP1A2CYP11B1CYP11B2
SCHEMBL1746656 0.84 HSD17B1 (0.69) PARP10PARP11CYP1A2CYP11B1CYP11B2
SCHEMBL28655414 0.84 HSD17B1 (0.78) PARP10PARP11CYP1A2CYP11B1CYP11B2
SCHEMBL1745161 0.82 HSD17B1 (0.71) PARP10PARP11CYP1A2CYP11B1CYP11B2
SCHEMBL24842505 0.80 HSD17B1 (0.54) PARP10PARP11CYP1A2CYP11B1CYP11B2
SCHEMBL13680642 0.80 PARP10 (0.64) PARP10PARP11CYP1A2CYP11B1CYP11B2
SCHEMBL3989386 0.80 CASP1 (0.66) PARP10PARP11CYP1A2CYP11B1CYP11B2
SCHEMBL31029247 0.80 CASP1 (0.59) CYP1A2CYP11B1CYP11B2HSD17B1CASP1
SCHEMBL28603 0.80 CASP1 (0.59) CYP1A2CYP11B1CYP11B2HSD17B1CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1183247-B1 POLYCYCLIC THIAZOLE SYSTEMS AND THEIR UTILIZATION AS ANORECTICS AVENTIS PHARMA GMBH (DE) 2005-05-25 EP disclosed
EP-1156805-B1 USE OF POLYCYCLIC THIAZOLE SYSTEMS FOR MANUFACTURING MEDICAMENTS FOR PREVENTING OR TREATING OBESITY AVENTIS PHARMA GMBH (DE) 2004-08-11 EP disclosed
EP-1183247-A1 POLYCYCLIC THIAZOLE SYSTEMS AND THEIR UTILIZATION AS ANORECTICS Aventis Pharma Deutschland GmbH (DE) 2002-03-06 EP disclosed
US-6329407-B1 ANOREXOGENIC AGENTS AVENTISPHARMA DEUTSCHLAND GMBH (DE) 2001-12-11 US disclosed
EP-1156805-A2 USE OF POLYCYCLIC THIAZOLE SYSTEMS FOR PRODUCING MEDICAMENTS FOR PREVENTING OR TREATING OBESITY Aventis Pharma Deutschland GmbH (DE) 2001-11-28 EP disclosed
US-6187801-B1 6-CHLORO-2-METHYL-8H-INDENO(1,2-D)-THIAZOLE HYDROCHLORIDE, FOR EXAMPLE; ADMINISTERING TO TREAT OBESITY, DIABETES; ANORECTICS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-02-13 US disclosed
WO-2000051997-A1 POLYCYCLIC THIAZOLE SYSTEMS AND THEIR UTILIZATION AS ANORECTICS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-09-08 WO disclosed
WO-2000051579-A2 USE OF POLYCYCLIC THIAZOLE SYSTEMS FOR PRODUCING MEDICAMENTS FOR PREVENTING OR TREATING OBESITY AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-09-08 WO disclosed